The International Generic and Biosimilar Medicines Association’s (IGBA) newly established CEO Advisory Committee held its first in-person meeting in Geneva this week and had a far-reaching exchange with the World Health Organization’s (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus and other WHO leaders. This was the first opportunity for Dr. Tedros to engage in a direct dialogue with the IGBA CEO Advisory Committee following its launch and the admission of IGBA as a non-State actor in official relations with WHO earlier this year.
The International Generic and Biosimilar Medicines Association (IGBA) announced today that it has appointed a Chair and Vice-Chair for its newly established Committee. Richard Saynor, CEO Sandoz, has been nominated as inaugural Chair, and Vinita Gupta, CEO Lupin, has been appointed Vice-Chair, both effective January 1, 2023, for a term of one year.
- WHO-South Korea biomanufacturing training hub initiative (September 2022)
- Generic and Biosimilar Medicines, Central to Patient Health and Global Healthcare Policies (September 2022)
- ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine (28 July 2022)
- UICC announces a new global coalition to increase access to and the use of essential cancer medicines in low- and lower middle-income countries (May 2022)
